Browsing by Author "Kefeli, Umut"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Comparison of second line treatment outcomes between sensitive and refractory small cell lung cancer patients: A retrospective analysis
    (Elsevier, 2012-09) Korkmaz, Taner; Seber, Selçuk; Sarı, Eyüp; Ustaalioğlu, Başak Oven; Kefeli, Umut; Balvan, Özlem; Gümuş, Mahmut; Yaşar, Nurgül; Turhal, Nazım Serdar; Canhoroz, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.
  • No Thumbnail Available
    Item
    Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: A retrospective analysis
    (Springer, 2013-07) Korkmaz, Taner; Seber, Selçuk; Kefeli, Umut; Sarı, Enes; Öven, Bala Başak; Yıldırım, Emre; Yaşar, Nurgül; Balvan, Özlem; Şener, Nur Dinç ; Yüksel, Sinemis; Güven, Aslıhan Mert; Polat, Özge; Yumuk, Perran Fulden; Gümüş, Mahmut; Turhal, Nazım Serdar; Canhoroz, Mustafa; Aydın, Dinçer; Kanat, Özkan; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; CJW-6018-2022; CCE-1550-2022; CYM-0930-2022; 52663246200; 55438191100; 55881548500
    Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods: We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results: Median age of group was 58. 82 % had an ECOG PS of 0-1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion: Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
  • No Thumbnail Available
    Publication
    Real-world treatment outcomes from nationwide onco-colon turkey registry in ras wild-type patients treated with biologics first-line metastatic colorectal cancer.
    (Lippincott Williams & Wilkins, 2021-05-20) Kefeli, Umut; Arslan, Cagatay; Yildirim, Mahmut Emre; Isikdogan, Abdurrahman; Karadurmus, Nuri; Karabulut, Bulent; Cubukcu, Erdem; Cicin, Irfan; Yalcin, Suayib; Turk, Haci M.; Bilir, Cemil; Karaca, Mustafa; Artac, Mehmet; Sendur, Mehmet Nahit; Alacacioglu, Ahmet; Simsek, Eda Tanrikulu; Dane, Faysal; Bilici, Ahmet; Cevik, Duygu; Gumus, Mahmut; Cubukcu, Erdem; ÇUBUKÇU, ERDEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; ETP-1691-2022